Table 3.
Model 1 OR (95% CI) |
Model 2 OR (95% CI) |
Model 3 OR (95% CI) |
Model 4 OR (95% CI) |
Model 5 OR (95% CI) |
Model 6 OR (95% CI) |
Model 7 OR (95% CI) |
|
---|---|---|---|---|---|---|---|
Opioid use | |||||||
No use | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
≤ 50 mg | 1.99 (1.19–3.31) |
1.45 (0.87–2.41) |
1.12 (0.67–1.85) |
2.00 (1.24–3.22) |
1.84 (1.11–3.06) |
1.71 (1.03–2.82) |
1.08 (0.65–1.79) |
> 50 mg | 3.32 (1.43–7.69) |
2.95 (1.30–6.68) |
1.81 (0.81–4.04) |
3.25 (1.47–7.20) |
3.09 (1.35–7.10) |
2.96 (1.30–6.78) |
2.65 (1.17–5.98) |
Pain Characteristics | |||||||
Pain Severity | 1.40 (1.25–1.56) |
1.05 (0.93–1.19) |
|||||
Pain Duration (yrs) | 1.01 (0.99–1.03) |
1.02 (0.99–1.04) |
|||||
Health Related Quality of Life | |||||||
SF-Pain Interfere | 0.97 (0.96–0.99) |
0.98 (0.96–0.99) |
|||||
SF-Physical Func | 0.99 (0.98–1.00) |
0.99 (0.98–1.01) |
|||||
SF-Physical Role | 1.00 (0.99–1.01) |
1.00 (0.99–1.01) |
|||||
SF-Gen Health | 0.97 (0.96–0.98) |
0.99 (0.98–1.00) |
|||||
Comorbidities | |||||||
# comorbidities | 1.11 (0.99–1.26) |
1.04 (0.92–1.19) |
|||||
Anxiety: | 12.13 (6.50–22.64) |
8.33 (4.39–15.81) |
|||||
Obese/over weight | 1.29 (0.68–2.42) |
0.87 (0.45–1.69) |
|||||
Psychosocial characteristics | |||||||
# stressful people | 1.50 (1.17–1.93) |
1.32 (1.05–1.65) |
|||||
# support people | 0.78 (0.67–0.92) |
0.92 (0.81–1.06) |
|||||
Demographic characteristics | |||||||
Age: | |||||||
≥ 60 | 0.80 (0.38–1.70) |
0.72 (0.34–1.53) |
|||||
46–59 | 1.46 (0.73–2.90) |
1.10 (0.59–2.05) |
|||||
18–45 | 1.00 | 1.00 | |||||
Race: Non-white | 1.73 (0.97–3.10) |
1.75 (1.03–2.98) |
|||||
Education: < high school | 3.03 (1.46–6.27) |
1.57 (0.83–2.98) |
|||||
Gender: female | 0.82 (0.44–1.52) |
0.61 (0.35–1.05) |
|||||
Disability Status: On/apply | 3.28 (1.82–5.92) |
1.00 (0.59–1.70) |
|||||
Model Information | |||||||
Pseudo R-square | 19.25% | 25.42% | 36.82% | 30.60% | 21.44% | 24.92% | 48.28% |
AIC | 914.40 | 873.70 | 781.10 | 759.56 | 899.55 | 879.32 | 667.30 |
All models adjusted for years since baseline assessment.